KD-182

N/A

Report date: 2022/07/22 16:15:44

Base Information

Drug NameKD-182
Drug Alias NameKD-182
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsStomach NeoplasmsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Kaidi Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Kaidi Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A